Onco-D-clare is a cancer screening test based on the interaction of molecular biology with machine learning algorithms. This screening test can help detect cancer before symptoms appear.
Peripheral blood mononuclear cells are isolated from blood samples, and gene expression analysis is performed in more than 90 genes. Their expression profile is then used for the classification of the sample as cancerous or healthy.
The Onco-D-clare test provides individuals with essential information to help them make better-informed decisions about future health and well-being.
The test is clinically validated and highly accurate (≈93%).
All types of cancer except brain and CNS (central nervous system) cancers
Final results
7-10 days after sample delivery
Sample size
5-8 ml peripheral whole blood
Price*
800 €
* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.
* RGCC is not liable for any third-party comments or claims regarding our products. For accurate and up-to-date information about our offerings, please refer to our official website: rgcc-international.com
